Search peptides, terms, sources/
Metabolic and incretin

Semaglutide

GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

2 findings at this grade. 1 further finding at this grade showed no effect and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials4 human trials · 1 lab (in-vitro)

What is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist studied in type 2 diabetes, weight management, cardiovascular outcomes and liver disease. In the UK it is a prescription-only medicine, licensed by the MHRA for specific indications. The research includes large placebo-controlled randomised trials.

It is modified to resist breakdown in the body, so it lasts longer. The liver research is in metabolic dysfunction-associated steatohepatitis (MASH), and a trial in Alzheimer's disease has so far been negative.

Class
GLP-1 receptor agonist, Incretin mimetic
Origin
Analogue / modified
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Semaglutide work?

Semaglutide copies a natural gut hormone called GLP-1. It binds the GLP-1 receptor, which makes the pancreas release insulin when blood sugar is high, slows stomach emptying and acts on brain areas that control appetite. A fatty-acid chain keeps it in the blood for about a week.

The mechanism in more detail

Semaglutide is a 31-amino-acid analogue of human GLP-1(7-37), engineered with an amino-acid substitution and a fatty-acid side chain that binds albumin, extending its plasma half-life to approximately one week and conferring resistance to breakdown by the enzyme DPP-4. This structural modification gives it a long half-life of about one week.

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the hypothalamus and brainstem, and the gastrointestinal tract. Receptor activation has been shown to raise intracellular cAMP signalling, which increases glucose-dependent insulin secretion and suppresses glucagon release from pancreatic islets.

Separately, central GLP-1 receptor activation in the hypothalamus and brainstem has been studied for its effects on appetite and food intake, and gastric emptying is reported to be delayed with GLP-1 receptor activation. Together, these mechanisms are proposed in the literature as the basis for reduced energy intake and weight loss observed in trials of semaglutide; this mechanistic account is drawn from receptor-pharmacology and review literature rather than a single primary structural-biology study.

Classification and structure

Names
Semaglutide; Ozempic (T2D brand); Wegovy (weight management/MASH brand); Rybelsus (oral T2D brand); research code NN9535/OG217SC
Class
GLP-1 receptor agonist Incretin mimetic
Origin
Analogue / modified
Structure
31-amino-acid peptide, synthetic analogue of human GLP-1(7-37) with approximately 94% sequence homology, modified with an Aib8 substitution and a C18 fatty di-acid side chain (via a glutamic acid/AEEA linker) at Lys26 for albumin binding, extending plasma half-life to approximately one week and conferring resistance to DPP-4 degradation.
Routes used in the research
Subcutaneous injection in the STEP and SELECT trial programmes. A separate oral tablet formulation was used in the EVOKE and EVOKE+ Alzheimer's trials and is the form of the licensed Rybelsus and oral Wegovy products.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Semaglutide has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
11031

1 of the findings graded Strong showed no effect, so it is not counted in the evidence grade at the top of the page.

Weight change at 68 weeks Strong

In adults with overweight or obesity without diabetes, subcutaneous semaglutide (the weight-management form) plus lifestyle intervention produced significantly greater weight loss than placebo (mean -14.9% vs -2.4% body weight at 68 weeks in the trial's primary analysis population; reported elsewhere as approximately a -10.1 percentage-point placebo-subtracted difference across analyses).

Study type
Human trial
Population
1,961 adults, BMI 30 or above (or 27 or above with 1 or more weight-related comorbidity), without diabetes; 68-week, phase 3, double-blind, placebo-controlled, multicentre (STEP 1).
Source
1 Wilding et al., 2021

Limitation: Sponsor-funded (Novo Nordisk); efficacy shown for the injectable weight-management form specifically, not automatically generalisable to the oral tablet; STEP 1 extension data show substantial weight regain after treatment withdrawal.

Weight regain after withdrawal Limited

Weight loss achieved with semaglutide during the STEP 1 trial was substantially regained after treatment discontinuation; at one year post-withdrawal, participants had regained on average two-thirds of their prior weight loss, and cardiometabolic improvements (blood pressure, lipids, HbA1c) similarly reversed toward baseline.

Study type
Human trial
Population
STEP 1 trial extension, subset of original STEP 1 participants followed after treatment withdrawal.
Source
2 Wilding et al., 2022

Limitation: Extension analysis of a trial not originally powered for this specific withdrawal-effect question; single study.

The SELECT cardiovascular trial Strong

In adults with pre-existing cardiovascular disease and overweight/obesity but without diabetes, injectable semaglutide (the weight-management form) reduced major adverse cardiovascular events (a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) by 20% versus placebo over a median 39.8-month follow-up (SELECT trial), and at 208 weeks was associated with mean weight reduction of -10.2%.

Study type
Human trial
Population
17,604 adults aged 45 or above with BMI 27 or above and established cardiovascular disease, without diabetes; multicentre, double-blind, placebo-controlled, phase 3.
Source
3 Lincoff et al., 2023

Limitation: Population is specifically overweight/obese adults with pre-existing cardiovascular disease, not generalisable without qualification to a primary-prevention population; sponsor-funded.

The EVOKE Alzheimer's trials Strong No effect shown

In two large phase 3 randomised, placebo-controlled trials (EVOKE and EVOKE+) in participants with amyloid-confirmed, early-stage symptomatic Alzheimer's disease, oral semaglutide did not demonstrate superiority to placebo in slowing cognitive or global clinical decline over 104 weeks, despite improvements in some disease biomarkers.

Study type
Human trial
Population
3,808 participants across two trials, aged 55 to 85, mild cognitive impairment or mild dementia due to Alzheimer's disease, 566 sites, 40 countries.
Source
4 The Lancet, 2026

Limitation: A negative/null result at the primary endpoint; biomarker changes were observed without corresponding clinical benefit, illustrating that mechanistic plausibility did not translate to a clinical effect in this population.

UK conditional marketing authorisation Not graded

Injectable semaglutide (the weight-management product) received UK conditional marketing authorisation on 3 July 2026 for metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, with the MHRA requiring further confirmatory efficacy/safety data from an ongoing study before full marketing authorisation can be granted.

Study type
Regulatory-clinical source
Population
Not applicable; regulatory decision, not a discrete study population.
Source
5 MHRA

Limitation: Conditional authorisation specifically means the underlying confirmatory evidence is not yet complete; this is not a strong-evidence claim about MASH efficacy, it is a regulatory decision made pending further data.

GLP-1 receptor mechanism Preliminary

Semaglutide is a synthetic GLP-1 receptor agonist, structurally modified to resist dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, extending its plasma half-life to approximately one week; GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite via central hypothalamic/brainstem receptor activation.

Study type
Lab (in-vitro)
Population
Receptor-pharmacology and mechanistic review literature; not a single clinical population.
Source
6 PMC

Limitation: Synthesised from multiple review-level (secondary) sources rather than one primary structural-biology paper; adequate for mechanism/background use, not for a specific numeric efficacy claim.

What safety findings have been reported?

5 safety findings are recorded for Semaglutide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Gastrointestinal adverse effects

Gastrointestinal effects (nausea, vomiting, and diarrhoea) are the most commonly reported adverse effects of GLP-1 receptor agonists including semaglutide; usually mild but can in some cases progress to severe dehydration requiring hospital treatment.

Source
7 MHRA, 2026

Rare acute pancreatitis reports

Rare reports of acute pancreatitis have been associated with GLP-1 receptor agonist use, including fatal outcomes in rare cases, per MHRA post-marketing surveillance; a causal relationship with any single agent has not been definitively established from the evidence reviewed.

Source
7 MHRA, 2026

NAION vision reports

Very rare reports of non-arteritic anterior ischaemic optic neuropathy (NAION), a vision problem, have been linked specifically to semaglutide by the MHRA.

Source
7 MHRA, 2026

Mixed suicidal-ideation evidence

A comprehensive MHRA review (aligned with an EMA PRAC review of approximately 150 case reports) concluded that available evidence does not support a causal association between GLP-1 receptor agonists (including semaglutide) and suicidal ideation, self-harm, or depression, though a separate pharmacovigilance-database study (WHO VigiBase, reported via JAMA Network Open) found semaglutide associated with a higher reporting rate of suicidal ideation relative to other drugs in that disproportionality analysis. Both are entered as reported findings; they are not fully reconciled, and the finding should be presented as genuinely mixed rather than resolved.

Source
8 EMA

Counterfeit product risks

Counterfeit or falsified semaglutide products, including unauthorised powder-in-vial formulations requiring reconstitution, have been identified circulating outside licensed pharmacy supply chains in the UK and pose distinct safety risks, including in some counterfeit-pen cases a risk of severe hypoglycaemia from mislabelled insulin content.

Source
9 MHRA

What is Semaglutide's UK regulatory status?

Marketing authorisation
Licensed: multiple marketing authorisations held (Ozempic, Wegovy injectable, Wegovy tablet, Rybelsus), each for a specific indication. Not a single blanket status.
Prescription status
Prescription-only medicine (POM) for all authorised presentations.
Medicine class
Licensed medicinal product (multiple authorised presentations).
MHRA position
MHRA-authorised for type 2 diabetes (Ozempic injectable, Rybelsus oral); weight loss/management in adults with obesity or overweight with a comorbidity (Wegovy injectable and, as of 11 June 2026, the Wegovy oral tablet); and metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (Wegovy injectable, conditional marketing authorisation granted 3 July 2026, pending confirmatory data).
Authorised use
Type 2 diabetes mellitus (injection and tablet products). Weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or above, or 27 or above with a weight-related condition (injection and tablet), and in adolescents aged 12 and over with obesity (injection). Reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight (injection). Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (injection; conditional authorisation). Not licensed for Alzheimer's disease.
Research use
Not applicable in the unlicensed research-chemical sense used for other peptides on this catalogue. Semaglutide is a licensed medicine and any research use is governed by standard clinical-trial/MHRA CTA frameworks.
Other restrictions
NHS availability is separate from MHRA authorisation and depends on NICE technology appraisal (NICE TA875 covers weight management; the MASH indication was, as of the source checked, still under NICE appraisal). MHRA has explicitly warned that safety and effectiveness outside licensed use, such as weight loss in people who are not obese or overweight, has not been assessed.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

10 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2032183 · Original ↗
  2. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8):1553-1564Human clinical trial · DOI 10.1111/dom.14725 · PMID 35441470 · Original ↗
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2307563 · Original ↗
  4. The Lancet (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The LancetHuman clinical trial, RCT · Original ↗
  5. MHRA Semaglutide (Wegovy) approved to treat form of liver disease. GOV.UK (MHRA) · Original ↗
  6. PMC A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. PMC (review literature) · Original ↗
  7. MHRA (UK government body) (2026). GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UKGovernment guidance · Original ↗
  8. European Medicines Agency (EMA) Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024. EMA (europa.eu) · Original ↗
  9. MHRA MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report misuse. GOV.UK · Original ↗
  10. eMC (2026). Semaglutide injection (weight-management product): Summary of Product Characteristics, eMC. electronic Medicines Compendium (eMC) · Original ↗

Questions about Semaglutide

What is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist studied in type 2 diabetes, weight management, cardiovascular outcomes and liver disease. In the UK it is a prescription-only medicine, licensed by the MHRA for specific indications. The research includes large placebo-controlled randomised trials. Read what it is.

Is Semaglutide licensed in the UK?

PeptGuru records Semaglutide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Semaglutide show?

PeptGuru records 6 research findings for Semaglutide: 4 from human trials, 1 regulatory decision and 1 laboratory and review source on how it works. The trials cover weight change, cardiovascular events and Alzheimer's disease, where no effect was shown. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Semaglutide?

5 safety findings are recorded, including: gastrointestinal adverse effects; rare acute pancreatitis reports; NAION vision reports. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Semaglutide?

All 10 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · UK status re-checked against the official product information. Added two licensed uses that were missing: reducing major cardiovascular events in adults with heart disease and obesity or overweight, and weight management in adolescents aged 12 and over.

How findings are graded: the grading method. All changes.

  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Mazdutide

    Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Semaglutide with Liraglutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.